01 5Bevespi
02 5Breztri
03 3Brovana
04 1Duaklir
05 8Dulera
06 1Foradil
07 6Symbicort
08 3Symbicort
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,721
2019 Revenue in Millions : 2,495
Growth (%) : 9
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 0
2019 Revenue in Millions : 213
Growth (%) : -100
Budesonide, Glycopyrronium and Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 2
Growth (%) : 1,300
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 48
2019 Revenue in Millions : 42
Growth (%) : 14
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 2,728
2020 Revenue in Millions : 2,721
Growth (%) : 0
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 54
2020 Revenue in Millions : 48
Growth (%) : 13
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 203
2020 Revenue in Millions : 28
Growth (%) : 625
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 190
2020 Revenue in Millions : 222
Growth (%) : -14
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 58
2021 Revenue in Millions : 54
Growth (%) : 7
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 398
2021 Revenue in Millions : 203
Growth (%) : 96
LOOKING FOR A SUPPLIER?